Masseter Muscle Hypertrophy
8
0
1
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
25%
2 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (8)
Ultrasonographic Evaluation of Masseter Muscle Changes After Botulinum Toxin Injection in Bruxism Patients
Comparison of Dry Needling and Two Botulinum Toxins for Bruxism
Changes in Electromyographic Activity in Aligner Treatment of Adult Patients With and Without Nocturnal Bruxism
Investigating the Effects of Smartphone Use on the Masseter Muscle
Effect of Different Treatment Techniques on Masseter Muscle Thickness
MEDITOXIN® Treatment in Subject With Benign Masseteric Hypertrophy
Botulinum Toxin Type A (BOTOX®) Treatment of Masseter Muscle Hypertrophy
Xeomin Cosmetic in the Management of Masseter